Stem Cell Evidence
LightNews LightNews
banner
stemcellevidence.bsky.social
Stem Cell Evidence
@stemcellevidence.bsky.social
140 followers 510 following 140 posts
Curating the evidence in haematopoietic stem cell transplantation. Free monthly Stem Cell Evidence Alert http://bit.ly/2HMQtb5 @[email protected]
#MedSky
Posts Replies Media Videos
stemcellevidence.bsky.social
New from #StemCellEvidence:

Machine Learning Algorithm to Explore Patients With Heterogeneous Treatment Effects of Clinically Significant CMV Infection and Non-Relapse Mortality After HSCT
by Toya et al.
www.stemcellevidence.com/articles/407...
#MedSky
Image showing a PICO summary for: Machine Learning Algorithm to Explore Patients With Heterogeneous Treatment Effects of Clinically Significant CMV Infection and Non-Relapse Mortality After HSCT by Toya et al. featured in the Stem Cell Evidence Alert - October 2025
November 11, 2025 at 7:00 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia (...)
by Ru et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Ru et al. featured in the Stem Cell Evidence Alert - October 2025
November 10, 2025 at 11:13 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
by Lee et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation by Lee et al. featured in the Stem Cell Evidence Alert - October 2025
November 7, 2025 at 1:10 PM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Serologic Characteristics and Clinical Significance of Non-ABO Red Blood Cell Antibodies in Hematopoietic Stem Cell Transplant. The BEST Collaborative Study
by Kogler et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: Serologic Characteristics and Clinical Significance of Non-ABO Red Blood Cell Antibodies in Hematopoietic Stem Cell Transplant. The BEST Collaborative Study by Kogler et al. featured in the Stem Cell Evidence Alert - October 2025
November 6, 2025 at 2:06 PM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Carbapenemase-Producing Enterobacteriaceae Colonization and the Risk of Carbapenemase-Producing Enterobacteriaceae Bacteremia in Hematopoietic Stem Cell Transplant Recipients
by Kang et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: Carbapenemase-Producing Enterobacteriaceae Colonization and the Risk of Carbapenemase-Producing Enterobacteriaceae Bacteremia in Hematopoietic Stem Cell Transplant Recipients by Kang et al. featured in the Stem Cell Evidence Alert - October 2025
November 5, 2025 at 7:36 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation
by Fujii et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation by Fujii et al. featured in the Stem Cell Evidence Alert - October 2025
November 4, 2025 at 10:27 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study
by Della Pepa et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study by Della Pepa et al. featured in the Stem Cell Evidence Alert - October 2025
November 3, 2025 at 9:43 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry
by Cohen et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry by Cohen et al. featured in the Stem Cell Evidence Alert - October 2025
October 31, 2025 at 10:43 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial
by Balduzzi et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial by Balduzzi et al. featured in the Stem Cell Evidence Alert - October 2025
October 30, 2025 at 8:30 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT) (...)
by Clark et al.
www.stemcellevidence.com/articles/409...
#MedSky
Image showing a PICO summary for: UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI) by Clark et al. featured in the Stem Cell Evidence Alert - October 2025
October 29, 2025 at 7:33 AM
stemcellevidence.bsky.social
The #StemCellEvidence monthly alert is out!

See all the top 10 articles here:
www.stemcellevidence.com/alerts/latest
Each one has an easy-to-read PICO summary.
#MedSky
Image of an extract of the Stem Cell Evidence Alert - October 2025
October 28, 2025 at 3:34 PM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Long-Term Efficacy of Epstein-Barr Virus-Specific T Cells for Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation (...)
by Sun et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Long-Term Efficacy of Epstein-Barr Virus-Specific T Cells for Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation: A Real-World Study by Sun et al. featured in the Stem Cell Evidence Alert - September 2025
October 13, 2025 at 8:55 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy (TA-TMA)
by Schoettler et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy (TA-TMA) by Schoettler et al. featured in the Stem Cell Evidence Alert - September 2025
October 10, 2025 at 12:32 PM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants
by Saliba et al.
www.stemcellevidence.com/articles/407...
#MedSky
Image showing a PICO summary for: Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants by Saliba et al. featured in the Stem Cell Evidence Alert - September 2025
October 9, 2025 at 11:42 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (...)
by Robin et al.
www.stemcellevidence.com/articles/407...
#MedSky
Image showing a PICO summary for: Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial by Robin et al. featured in the Stem Cell Evidence Alert - September 2025
October 8, 2025 at 9:18 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Neurological manifestations of chronic graft versus host disease
by Koren et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Neurological manifestations of chronic graft versus host disease by Koren et al. featured in the Stem Cell Evidence Alert - September 2025
October 7, 2025 at 6:38 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT
by Hernández-Boluda et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT by Hernández-Boluda et al. featured in the Stem Cell Evidence Alert - September 2025
October 6, 2025 at 8:51 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood (...)
by Capes et al.
www.stemcellevidence.com/articles/407...
#MedSky
Image showing a PICO summary for: Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation by Capes et al. featured in the Stem Cell Evidence Alert - September 2025
October 3, 2025 at 11:03 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGvHD biomarkers
by Caballero-Velázquez et al.
www.stemcellevidence.com/articles/407...
#MedSky
Image showing a PICO summary for: Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGvHD biomarkers by Caballero-Velázquez et al. featured in the Stem Cell Evidence Alert - September 2025
October 2, 2025 at 6:30 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party
by Berning et al.
www.stemcellevidence.com/articles/408...
#MedSky
Image showing a PICO summary for: Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party by Berning et al. featured in the Stem Cell Evidence Alert - September 2025
October 1, 2025 at 8:11 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
by Stelljes et al.
www.stemcellevidence.com/articles/407...
#MedSky
Image showing a PICO summary for: Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial by Stelljes et al. featured in the Stem Cell Evidence Alert - September 2025
September 30, 2025 at 9:56 AM
stemcellevidence.bsky.social
The #StemCellEvidence monthly alert is out!
See all the top 10 articles here:
www.stemcellevidence.com/alerts/latest
Each one has an easy-to-read PICO summary.
#MedSky
Image showing an extract of the Stem Cell Evidence Alert - September 2025
September 29, 2025 at 9:21 AM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
by Zeiser et al.

www.stemcellevidence.com/articles/405...

#MedSky
Image showing a PICO summary for: Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study by Zeiser et al. Featured in Stem Cell Evidence Alert – August 2025
September 12, 2025 at 11:46 AM
stemcellevidence.bsky.social
New from #StemCellEvidence:

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
by Perales et al.

www.stemcellevidence.com/articles/406...

#MedSky
Image showing a PICO summary for: Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis by Perales et al. Featured in Stem Cell Evidence Alert – August 2025
September 11, 2025 at 1:04 PM
stemcellevidence.bsky.social
From the #StemCellEvidence Alert:

Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center
By Oran et al.

www.stemcellevidence.com/articles/407...
#MedSky
September 10, 2025 at 11:52 AM